Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21579789 | 0.85 | TSHR (0.35) | TSHR | |
| SCHEMBL20227048 | 0.80 | — | — | |
| SCHEMBL29161532 | 0.80 | LMNA (0.36) | TSHR | |
| SCHEMBL20179585 | 0.80 | KDM4C (0.32) | KDM4C | |
| SCHEMBL22764114 | 0.80 | LMNA (0.36) | KDM4C | |
| SCHEMBL19563496 | 0.78 | — | — | |
| SCHEMBL19403838 | 0.75 | — | — | |
| SCHEMBL7961911 | 0.74 | TSHR (0.32) | TSHR | |
| SCHEMBL276710 | 0.71 | TSHR (0.38) | TSHR | |
| SCHEMBL9288689 | 0.70 | SIGMAR1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230202993-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2023-06-29 | — | — | US | disclosed |
| US-11197864-B2 | Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis | Biohaven Pharmaceutical Holding Company Limited (US) | 2021-12-14 | — | — | US | disclosed |
| US-20210163447-A1 | TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | BLACK DIAMOND THERAPEUTICS, INC. | 2021-06-03 | — | — | US | disclosed |
| US-20210078962-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2021-03-18 | — | — | US | disclosed |
| US-10357497-B2 | Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis | Biohaven Pharmaceutical Holding Company Limited (US) | 2019-07-23 | — | — | US | disclosed |
| US-9657022-B2 | 7-OXO-1,6-diazabicyclo[3.2.1]octane derivatives and their use as antibacterial agents | WOCKHARDT LIMITED (IN) | 2017-05-23 | — | — | US | disclosed |
| US-20170044159-A1 | 7-OXO-1,6-DIAZABICYCLO[3.2.1 ]OCTANE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | WOCKHARDT LIMITED (IN) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10357497-B2 | Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis | CYP1A2, CYP3A5, UGT1A1 | TSHR 4429/4885KDM4C 2729/4885 |
| US-11197864-B2 | Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis | CYP1A2, UGT1A1, SMN1; SMN2 | TSHR 4562/4885KDM4C 2791/4885 |
| US-20230202993-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | APEH, UGT1A9, ALDH3A1 | TSHR 3349/4885KDM4C 747/4885 |
| US-20210078962-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | APEH, UGT1A9, ALDH3A1 | TSHR 3349/4885KDM4C 747/4885 |
| US-20210163447-A1 | TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | ERBB2, ERBB3, EGFR | TSHR 971/4885KDM4C 1688/4885 |
| US-20170044159-A1 | 7-OXO-1,6-DIAZABICYCLO[3.2.1 ]OCTANE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | CASP7, ODC1, CASP1 | TSHR 3441/4885KDM4C 4452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.